11 results on '"Flori, Maria"'
Search Results
2. The psychological burden in psoriatic patients beyond PASI.
- Author
-
Russo, Filomena, Flori, Maria L., and Mancini, Virginia
- Subjects
- *
PSORIASIS , *PSYCHOCUTANEOUS diseases , *PSORIASIS treatment , *PHYSICIAN-patient relations , *PATIENT compliance , *PSYCHOLOGY - Published
- 2018
- Full Text
- View/download PDF
3. Analysing the Stock Market as an Economic Lever, Using a Qualitative and a Quantitative Model.
- Author
-
Cristescu, Marian-Pompiliu, Nerișanu, Raluca-Andreea, Flori, Maria, Stoica, Florin, and Stoica, Florentina Laura
- Subjects
- *
STOCK exchanges , *QUANTITATIVE research , *ECONOMIC expansion , *ECONOMIC models , *MACROECONOMIC models - Abstract
The article aims to provide a perspective on economic growth by relying on the influence and use of the stock market as an economic lever. Two methods will be used: a quantitative one, determined by a multiple linear regression model, and a qualitative one that encumbers a sustainable vector model for generating economic growth. The data panel covers 36 states, for a period of 21 years. The paper manages to identify the main control functions that the stock exchange has over the macroeconomic context, through the quantitative and qualitative method, and to highlight the most important positive and negative attributes of using qualitative methods, in contrast to quantitative ones. The results show a predominant probabilistic characteristic of quantitative methods, in contrast to the flexibility and complexity of the qualitative method, which has been used. Additionally, the quantitative method offers a strictly cartesian perspective for determining future scenarios, while the sustainable vector model, based on a fractalized vision of reality, manages to capture a plurality of perspectives, as well as the interrelationships between the determining parameters, thus being a complex system of simple equations, as opposed to the quantitative method which is defined as a simple system of complex equations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. A paradoxical head and neck erythema: an adverse event due to dupilumab in adult patients with atopic dermatitis.
- Author
-
Russo, Filomena, Rizzo, Arianna, Santi, Francesco, Lamberti, Arianna, Lazzeri, Laura, Flori, Maria Laura, and Rubegni, Pietro
- Subjects
- *
ATOPIC dermatitis , *DUPILUMAB , *ECZEMA , *HEAD & neck cancer , *ERYTHEMA , *NECK , *ADULTS - Abstract
Despite the presence of this erythema and although the lesions did not respond to treatment, all patients continued with their dupilumab treatment with spontaneous remission of erythema within two to three months. 1 and Table 1) with severe AD treated with dupilumab and with paradoxical head and neck erythema that appeared 8-20 weeks after the start of biological treatment while eczema on other body parts had greatly improved. Dear Editor, Atopic dermatitis (AD) is a chronic inflammatory dermatological disease with multifactorial etiology. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
5. Usefulness of in vivo reflectance confocal microscopy in Morbihan syndrome.
- Author
-
Rizzo, Arianna, Fiorani, Diletta, Lazzeri, Laura, Taddeucci, Paolo, Rubegni, Pietro, Flori, Maria Laura, and Russo, Filomena
- Subjects
- *
CONFOCAL microscopy , *SYNDROMES , *REFLECTANCE , *HANSEN'S disease , *THERAPEUTICS - Abstract
The clinical presentation associated with RCM and histological examination confirmed the diagnosis of Morbihan syndrome rosacea associated. Morbihan syndrome is a rare dermatological condition characterized by chronic persistent erythema and firm edema of the face accompanied by telangiectasia, papules, or pustules.1-3 It is considered a complication of acne or rosacea. 5 Kutlay S, Ozdemir EC, Pala Z, Ozen S, Sanli H. Complete decongestive therapy is an option for the treatment of rosacea lymphedema (Morbihan Disease): two cases. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
6. Efficacy of Dupilumab in two patients with severe and recalcitrant atopic dermatitis previously treated with extracorporeal photopheresis.
- Author
-
Russo, Filomena, Taddeucci, Paolo, Lazzeri, Laura, Flori, Maria L., and Rubegni, Pietro
- Subjects
- *
ATOPIC dermatitis , *PATHOLOGY , *BIOTHERAPY , *DUPILUMAB , *PHOTOTHERAPY - Abstract
Atopic dermatitis (AD) is a complex disease and can often be a clinical challenge for dermatologists. When standard immunosuppressive therapies fail, extracorporeal phototherapy (ECP) can be considered as a therapeutic option. In recent years, better understanding of the pathogenesis of AD allowed to improve treatment strategies with many emerging therapeutic options. Currently, Dupilumab, a monoclonal antibody that selectively inhibits IL‐4 and IL‐13, is the only biological drug authorized for the treatment of severe adult atopic dermatitis, refractory to traditional firstline and secondline therapies. ECP, compared to biological therapy, is associated with some disadvantages: it is costly and time‐consuming for patients and personnel to administer. Moreover, it should be noted that the completion of the entire procedure takes about 3 hr and must be done in a hospital, while the administration of Dupilumab can be carried out by patients themselves at home. For these reasons and on the basis of our experience, it would be necessary to evaluate whether all patients with refractory atopic dermatitis in treatment with ECP with unsatisfactory clinical response should be switched to recent available target therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Amenorrhea secondary to vismodegib: An adverse event to consider especially in female patients with Gorlin‐Goltz syndrome.
- Author
-
Russo, Filomena, Provvidenziale, Luca, Mancini, Virginia, Lazzeri, Laura, Flori, Maria Laura, Taddeucci, Paolo, and Rubegni, Pietro
- Subjects
- *
BASAL cell nevus syndrome , *AMENORRHEA , *WOMEN patients , *BASAL cell carcinoma , *SPASMS , *VISMODEGIB - Published
- 2020
- Full Text
- View/download PDF
8. Altered expression of the α2 laminin chain in psoriatic skin: the effect of treatment with cyclosporin.
- Author
-
Toti, Pellegrino, Villanova, Flori, Miracco, Bartolommei, Andreassi, and Laura Flori, Maria
- Subjects
- *
PSORIASIS treatment , *CYCLOSPORINE , *SKIN wound treatment - Abstract
The histopathological pattern of psoriasis is characterized by dermal inflammatory reaction and hyperproliferation of the epidermis. The mechanism of the epidermal hyperproliferation is not completely understood, but it is probably modulated by the basal lamina (BL), the alterations of which have not been described. We performed the present study to evaluate the expression of the α1, α2, β1 and γ1 laminin chains and collagen IV in the BL of active psoriasis vulgaris before and after cyclosporin treatment administered until the psoriasis was in remission. The results showed that the α2 chain is weak and irregular in the lesions, while the α1, β1 and γ1 chains and collagen IV are normal, with intense and continuous reaction. In the same subjects, this alteration was absent in skin that was clinically unaffected. After treatment with cyclosporin, the altered expression of the α2 chain returned to normal in the healing lesions. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
9. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations.
- Author
-
Gisondi, Paolo, Talamonti, Marina, Chiricozzi, Andrea, Piaserico, Stefano, Amerio, Paolo, Balato, Anna, Bardazzi, Federico, Calzavara Pinton, Piergiacomo, Campanati, Anna, Cattaneo, Angelo, Dapavo, Paolo, De Simone, Clara, Dini, Valentina, Fargnoli, Maria C., Flori, Maria L., Galluzzo, Marco, Guarneri, Claudio, Lasagni, Claudia, Loconsole, Francesco, and Lo Schiavo, Ada
- Abstract
Introduction: Treat-to-target strategies are used in several chronic diseases to improve outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no consensus on targets, and guidance is needed to implement this strategy in clinical practice. The project ‘Treat to Target Italia’ was launched by a scientific board (SB) of 10 psoriasis experts to generate expert consensus recommendations.On the basis of the published literature, their clinical experience, and the results of a survey among Italian dermatologists, the SB identified four relevant topics: (1) clinical remission; (2) quality of life; (3) abrogation of systemic inflammation; (4) safety. They drafted 20 statements addressing these four topics and submitted them to a panel of 28 dermatologists, in a Delphi process, to achieve consensus (greater than 80% agreement).Consensus was reached on all statements. Treatment goals defining clinical remission should include a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI90 response) or an absolute PASI score of less than or equal to 3. Patient’s quality of life and satisfaction are important targets. If PASI targets are achieved, there should be no or very low impact of psoriasis on quality of life [Dermatology Life Quality Index (DLQI) score less than or equal to 3]. If PASI or DLQI goals are not achieved within 3–4 months, treatment should be changed. Abrogation of systemic inflammation may be crucial for preventing or delaying inflammatory comorbidities. Safety is an equally important target as efficacy.These 20 consensus statements define the parameters of a treat-to-target strategy for psoriasis in Italy. It is hoped that use of these in the management of patients with psoriasis will improve treatment outcomes and patient health-related quality of life.Methods: Treat-to-target strategies are used in several chronic diseases to improve outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no consensus on targets, and guidance is needed to implement this strategy in clinical practice. The project ‘Treat to Target Italia’ was launched by a scientific board (SB) of 10 psoriasis experts to generate expert consensus recommendations.On the basis of the published literature, their clinical experience, and the results of a survey among Italian dermatologists, the SB identified four relevant topics: (1) clinical remission; (2) quality of life; (3) abrogation of systemic inflammation; (4) safety. They drafted 20 statements addressing these four topics and submitted them to a panel of 28 dermatologists, in a Delphi process, to achieve consensus (greater than 80% agreement).Consensus was reached on all statements. Treatment goals defining clinical remission should include a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI90 response) or an absolute PASI score of less than or equal to 3. Patient’s quality of life and satisfaction are important targets. If PASI targets are achieved, there should be no or very low impact of psoriasis on quality of life [Dermatology Life Quality Index (DLQI) score less than or equal to 3]. If PASI or DLQI goals are not achieved within 3–4 months, treatment should be changed. Abrogation of systemic inflammation may be crucial for preventing or delaying inflammatory comorbidities. Safety is an equally important target as efficacy.These 20 consensus statements define the parameters of a treat-to-target strategy for psoriasis in Italy. It is hoped that use of these in the management of patients with psoriasis will improve treatment outcomes and patient health-related quality of life.Results: Treat-to-target strategies are used in several chronic diseases to improve outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no consensus on targets, and guidance is needed to implement this strategy in clinical practice. The project ‘Treat to Target Italia’ was launched by a scientific board (SB) of 10 psoriasis experts to generate expert consensus recommendations.On the basis of the published literature, their clinical experience, and the results of a survey among Italian dermatologists, the SB identified four relevant topics: (1) clinical remission; (2) quality of life; (3) abrogation of systemic inflammation; (4) safety. They drafted 20 statements addressing these four topics and submitted them to a panel of 28 dermatologists, in a Delphi process, to achieve consensus (greater than 80% agreement).Consensus was reached on all statements. Treatment goals defining clinical remission should include a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI90 response) or an absolute PASI score of less than or equal to 3. Patient’s quality of life and satisfaction are important targets. If PASI targets are achieved, there should be no or very low impact of psoriasis on quality of life [Dermatology Life Quality Index (DLQI) score less than or equal to 3]. If PASI or DLQI goals are not achieved within 3–4 months, treatment should be changed. Abrogation of systemic inflammation may be crucial for preventing or delaying inflammatory comorbidities. Safety is an equally important target as efficacy.These 20 consensus statements define the parameters of a treat-to-target strategy for psoriasis in Italy. It is hoped that use of these in the management of patients with psoriasis will improve treatment outcomes and patient health-related quality of life.Conclusion: Treat-to-target strategies are used in several chronic diseases to improve outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no consensus on targets, and guidance is needed to implement this strategy in clinical practice. The project ‘Treat to Target Italia’ was launched by a scientific board (SB) of 10 psoriasis experts to generate expert consensus recommendations.On the basis of the published literature, their clinical experience, and the results of a survey among Italian dermatologists, the SB identified four relevant topics: (1) clinical remission; (2) quality of life; (3) abrogation of systemic inflammation; (4) safety. They drafted 20 statements addressing these four topics and submitted them to a panel of 28 dermatologists, in a Delphi process, to achieve consensus (greater than 80% agreement).Consensus was reached on all statements. Treatment goals defining clinical remission should include a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI90 response) or an absolute PASI score of less than or equal to 3. Patient’s quality of life and satisfaction are important targets. If PASI targets are achieved, there should be no or very low impact of psoriasis on quality of life [Dermatology Life Quality Index (DLQI) score less than or equal to 3]. If PASI or DLQI goals are not achieved within 3–4 months, treatment should be changed. Abrogation of systemic inflammation may be crucial for preventing or delaying inflammatory comorbidities. Safety is an equally important target as efficacy.These 20 consensus statements define the parameters of a treat-to-target strategy for psoriasis in Italy. It is hoped that use of these in the management of patients with psoriasis will improve treatment outcomes and patient health-related quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Ocular involvement in generalized fixed drug eruption from nimesulide.
- Author
-
Rubegni, Pietro, Tognetti, Linda, Tosi, Gian Marco, Flori, Maria L, and Fimiani, Michele
- Subjects
- *
DRUG side effects , *NIMESULIDE , *OCULAR pharmacology - Abstract
A letter to the editor is presented regarding the case of a 59-year-old woman who suffered from irritation and foreign body sensation in the left eye, and was diagnosed with fixed drug eruption (FDE) triggered by nimesulide powder.
- Published
- 2013
- Full Text
- View/download PDF
11. Constitutional Skin Color in Caucasians.
- Author
-
Andreassi, Lucio, Rubegni, Pietro, Stanghellini, Elisabetta, Cevenini, Gabriele, Flori, Maria Laura, and Weatherall, Ian L.
- Subjects
- *
LETTERS to the editor , *HUMAN skin color - Abstract
Presents a letter to the editor concerning constitutional skin color in Caucasians, published in the May 1, 1996 issue of the "Journal of Investigative Dermatology."
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.